IGC Pharma, Inc. (IGC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IGC Pharma, Inc. (IGC) Healthcare & Pipeline Overview

IGC Pharma, Inc. is a clinical-stage biotechnology company specializing in Alzheimer's disease therapeutics, with a focus on IGC-AD1, a Phase 2 clinical trial drug targeting agitation in dementia. The company leverages artificial intelligence for research and development in the Alzheimer's space.

What Is the Investment Thesis for IGC?

IGC Pharma, Inc. presents a high-risk, high-reward investment opportunity for investors interested in the biotechnology sector, specifically in Alzheimer's disease therapeutics. The primary value driver is the successful completion of the Phase 2 clinical trial for IGC-AD1, which targets agitation in dementia due to Alzheimer's. Positive results could lead to significant market valuation increases. The company's focus on leveraging AI for drug discovery could also yield long-term benefits. However, the company's negative profit margin of -552.1% and reliance on future funding pose substantial risks. The relatively low Beta of 0.50 suggests lower volatility compared to the overall market, but the success of IGC Pharma hinges on clinical trial outcomes and regulatory approvals.

Based on FMP financials and quantitative analysis

IGC Key Highlights

• IGC Pharma is a clinical-stage pharmaceutical company focused on Alzheimer's disease.
• The company's lead drug candidate, IGC-AD1, is in Phase 2 clinical trials for agitation in dementia due to Alzheimer's.
• IGC Pharma leverages artificial intelligence (AI) for Alzheimer's research.
• The company's gross margin is 29.7%.
• IGC Pharma has a market capitalization of $26.7M.

Who Are IGC's Competitors?

IGC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IGC's Key Strengths?

• Focus on Alzheimer's disease, a significant unmet medical need.
• IGC-AD1 in Phase 2 clinical trials.
• Use of artificial intelligence for drug discovery.
• Experienced leadership team.

What Are IGC's Weaknesses?

• Negative profit margin (-552.1%).
• Reliance on future funding.
• Limited product pipeline beyond IGC-AD1 and TGR-63.
• Small market capitalization.

What Could Drive IGC Stock Higher?

• Announcement of Phase 2 clinical trial results for IGC-AD1 (expected in 2027).
• Initiation of clinical trials for TGR-63 (expected in 2028).
• Progress in AI-driven drug discovery efforts.
• Potential strategic partnerships and collaborations.

What Are the Key Risks for IGC?

• Financial-distress signal — its Altman Z-Score of -16.62 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-94.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of IGC-AD1 in Phase 2 clinical trials.
• Regulatory delays or rejection of IGC-AD1.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on future funding to support operations.
• Patent expirations on key drug candidates.

What Are the Growth Opportunities for IGC?

• Successful Phase 2 Clinical Trial for IGC-AD1: The successful completion of the Phase 2 clinical trial for IGC-AD1 represents a significant growth opportunity for IGC Pharma. Positive trial results could lead to accelerated regulatory approval and commercialization, potentially capturing a significant share of the Alzheimer's agitation treatment market. A successful trial outcome would not only validate IGC Pharma's technology but also attract potential partnerships and investment.
• Advancement of TGR-63 into Clinical Trials: The advancement of TGR-63, IGC Pharma's second drug asset, into clinical trials presents another growth opportunity. TGR-63, currently in pre-clinical development, targets a different aspect of Alzheimer's disease, potentially expanding IGC Pharma's therapeutic pipeline and market reach. The successful development of TGR-63 could diversify the company's revenue streams and reduce its reliance on IGC-AD1. The timeline for TGR-63's clinical development is estimated to be 3-5 years, with potential market entry by 2030 if trials are successful.
• Leveraging Artificial Intelligence for Drug Discovery: IGC Pharma's focus on leveraging artificial intelligence (AI) for drug discovery offers a long-term growth opportunity. AI can accelerate the identification of new drug targets, optimize drug development processes, and improve the efficiency of clinical trials. The AI in drug discovery market is projected to reach $5 billion by 2028, driven by advancements in machine learning and the increasing availability of data. IGC Pharma's AI initiatives could lead to the discovery of novel therapeutic candidates and a competitive advantage in the Alzheimer's disease market.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and technology providers represents a growth opportunity for IGC Pharma. Collaborations can provide access to additional resources, expertise, and funding, accelerating the development and commercialization of IGC Pharma's drug candidates. Potential partners include companies with complementary technologies, research institutions with expertise in Alzheimer's disease, and pharmaceutical companies with established distribution networks. Strategic alliances could enhance IGC Pharma's market position and increase its long-term growth potential.
• Expansion into International Markets: Expanding into international markets, particularly in Europe and Asia, offers a growth opportunity for IGC Pharma. Alzheimer's disease is a global health challenge, and there is significant demand for effective treatments in many countries. Entering new markets would require regulatory approvals, partnerships with local distributors, and investment in marketing and sales infrastructure. However, the potential rewards are substantial, as international expansion could significantly increase IGC Pharma's revenue and market share. The timeline for international expansion is estimated to be 3-5 years, with potential market entry by 2030.

What Opportunities Does IGC Have?

• Successful completion of Phase 2 clinical trial for IGC-AD1.
• Advancement of TGR-63 into clinical trials.
• Strategic partnerships and collaborations.
• Expansion into international markets.

What Threats Does IGC Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from larger pharmaceutical companies.
• Patent expirations.

What Are IGC's Competitive Advantages?

• Patented drug candidates: IGC-AD1 and TGR-63 are protected by patents, providing a competitive advantage.
• Clinical-stage development: Being in Phase 2 clinical trials gives IGC Pharma a head start over companies with earlier-stage assets.
• AI-driven research: Leveraging AI for drug discovery enhances efficiency and innovation.
• Specialized focus: Dedication to Alzheimer's disease allows for deep expertise and targeted solutions.

What Does IGC Do?

IGC Pharma, Inc., founded on April 29, 2005, by Ram Mukunda, is a clinical-stage pharmaceutical company dedicated to developing innovative solutions for Alzheimer's disease. Headquartered in Potomac, MD, the company's primary focus is on addressing the unmet medical needs in the treatment of Alzheimer's, a neurodegenerative disease affecting millions worldwide. IGC Pharma's pipeline includes two investigational drug assets targeting Alzheimer's disease. The lead drug candidate, IGC-AD1, is currently in a Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's disease. The second drug asset, TGR-63, is in the pre-clinical development stage. In addition to its drug development efforts, IGC Pharma seeks to leverage artificial intelligence (AI) to enhance its research capabilities and accelerate the discovery of new therapeutic targets and drug candidates for Alzheimer's disease. The company operates with a team of 67 employees, focusing on research, development, and clinical trials to bring novel treatments to market.

What Products and Services Does IGC Offer?

• Develops pharmaceutical solutions for Alzheimer's disease.
• Conducts Phase 2 clinical trials for IGC-AD1, a treatment for agitation in dementia due to Alzheimer's.
• Engages in pre-clinical development of TGR-63.
• Leverages artificial intelligence (AI) for Alzheimer's research.
• Focuses on addressing unmet medical needs in Alzheimer's treatment.
• Seeks to discover new therapeutic targets and drug candidates for Alzheimer's disease.

How Does IGC Make Money?

• Develops and commercializes pharmaceutical products for Alzheimer's disease.
• Generates revenue through the sale of approved drugs.
• Seeks partnerships and collaborations for research and development funding.
• Leverages intellectual property and patents to protect its drug candidates.

What Industry Does IGC Operate In?

IGC Pharma operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful drug candidates. The Alzheimer's disease therapeutics market is a growing area of focus due to the increasing prevalence of the disease and the lack of effective treatments. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop innovative solutions for Alzheimer's. IGC Pharma's focus on AI-driven drug discovery and its Phase 2 clinical trial for IGC-AD1 position it as a potential player in this competitive market.

Who Are IGC's Key Customers?

• Patients suffering from Alzheimer's disease.
• Healthcare providers and physicians who prescribe Alzheimer's treatments.
• Hospitals and clinics that administer Alzheimer's therapies.
• Pharmaceutical distributors and wholesalers.

ROE -95%Key Financial Metrics

Return on equity for IGC Pharma, Inc. stands at -94.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -71.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.40 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -25.7%, the inverse of the P/E and a quick read on earnings relative to price.

IGC Pharma, Inc. (IGC) Valuation Context

Valued at $26.7M, IGC is classified as a micro-cap stock. Relative to its peer group, IGC's quantitative score of 19/100 is below the peer average of 79/100.

Company Profile

IGC Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Potomac, US. The company is led by CEO Ram Mukunda. IGC has traded publicly since 2006.

F-Score 2/9Financial Health

IGC Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.62 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project IGC Pharma, Inc. revenue of about $869K for fiscal 2026, with EPS near $-0.05.

IGC Financials

IGC Latest News

IGC Analyst Consensus

IGC MoonshotScore

What Investors Ask About IGC Pharma, Inc. (IGC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources